Health Care [ 3/12 ] | Life Sciences Tools & Services [ 29/74 ]
NASDAQ | Common Stock
Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research.
The company's products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on.
Its products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and data analysis and bioinformatics services.
In addition, the company offers Olink normalized protein expression (NPX) data processing software, a purpose-built software that enable users to import data, perform data analysis including visualizations, and statistical modelling; and Olink Insight, a cloud platform for Olink community to accelerate proteomics.
It sells its products and services through its own direct sales force in Sweden, the United States, rest of the Americas, rest of Europe, the Middle East, Africa, Japan, and internationally.
The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021.
Olink Holding AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.
As of July 10, 2024, Olink Holding AB (publ) operates as a subsidiary of Thermo Fisher Scientific Inc..
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | -0.13 Decreased by -18.18% | -0.15 Increased by +13.33% |
| Mar 25, 24 | -0.06 Decreased by -220.00% | 0.15 Decreased by -140.00% |
| Nov 15, 23 | -0.01 Increased by 0.00% | -0.08 Increased by +87.50% |
| Aug 9, 23 | -0.07 Decreased by -75.00% | -0.10 Increased by +30.00% |
| May 11, 23 | -0.11 Decreased by -10.00% | -0.12 Increased by +8.33% |
| Feb 21, 23 | 0.05 Increased by +171.43% | 0.01 Increased by +400.00% |
| Nov 10, 22 | -0.01 Increased by +80.00% | -0.09 Increased by +88.89% |
| Aug 11, 22 | -0.04 Increased by +55.56% | -0.14 Increased by +71.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 28.59 M Increased by +4.12% | -15.97 M Decreased by -14.43% | Decreased by -55.87% Decreased by -9.90% |
| Dec 31, 23 | 69.27 M Increased by +19.67% | -7.63 M Decreased by -240.51% | Decreased by -11.01% Decreased by -217.41% |
| Sep 30, 23 | 44.15 M Increased by +38.97% | -1.82 M Decreased by -41.23% | Decreased by -4.12% Decreased by -1.63% |
| Jun 30, 23 | 29.44 M Increased by +6.99% | -8.27 M Decreased by -71.59% | Decreased by -28.11% Decreased by -60.38% |
| Mar 31, 23 | 27.46 M Increased by +21.08% | -13.96 M Decreased by -14.68% | Decreased by -50.83% Increased by +5.28% |
| Dec 31, 22 | 57.88 M Increased by +32.51% | 5.43 M Increased by +168.10% | Increased by +9.38% Increased by +151.39% |
| Sep 30, 22 | 31.77 M Increased by +59.07% | -1.29 M Increased by +76.46% | Decreased by -4.05% Increased by +85.20% |
| Jun 30, 22 | 27.51 M Increased by +55.55% | -4.82 M Increased by +54.51% | Decreased by -17.53% Increased by +70.76% |